LeonaBio, Inc.
LeonaBio, Inc. (Nasdaq Capital Market: LEON) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for high unmet medical needs, particularly in oncology and neurology. The company's website is www.leonabio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What LeonaBio, Inc. does
In the company’s own words
LeonaBio, Inc. (Nasdaq Capital Market: LEON) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for high unmet medical needs, particularly in oncology and neurology. The company's website is www.leonabio.com.
LeonaBio operates a pipeline of drug candidates focused on two primary therapeutic areas. The company's lead oncology asset is lasofoxifene, a selective estrogen receptor modulator currently in Phase 3 clinical development for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations. Lasofoxifene was in-licensed globally in December 2025, excluding Asia and certain Middle Eastern countries. The company's pivotal ELAINE-3 trial aims to demonstrate the superiority of lasofoxifene combined with abemaciclib compared to fulvestrant with abemaciclib for patients with ESR1-driven metastatic breast cancer following CDK4/6 inhibitor progression. As of December 2025, the trial had completed over fifty percent recruitment, with topline data anticipated in the second half of 2027.
In neurology, LeonaBio's lead candidate is ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system designed to treat amyotrophic lateral sclerosis. The company completed a first-in-human Phase 1 trial in November 2024, which demonstrated favorable safety and tolerability in eighty healthy volunteers. A Phase 2 proof-of-concept trial in ALS patients is anticipated to commence in 2026, with primary focus on plasma neurofilament light chain levels as a biomarker of neurodegeneration.
The company also maintains early-stage development programs including ATH-1020, another HGF system modulator being explored for neuropathic pain and other neurological indications, along with novel compounds in discovery targeting various molecular pathways relevant to oncology and neurology applications.
LeonaBio has incurred significant losses since inception and anticipates continued losses through the foreseeable future as it advances clinical development programs. The company is classified as a smaller reporting company and is not a well-known seasoned issuer. As of March 27, 2026, the company had 9,393,514 shares of common stock outstanding.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- BOTHELL, WA
- Fiscal year end
- December
- CIK
- 1620463
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns LeonaBio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · LeonaBio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do LeonaBio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of LeonaBio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in LeonaBio, Inc.'s last four quarterly filings that the numbers alone won't show?”